6271-81-4

Usage

Uses

Used in Pharmaceutical Synthesis:
5-methoxynaphthalen-1-amine is utilized as a key intermediate in the synthesis of pharmaceuticals for its ability to engage in multiple chemical reactions. Its presence in the molecular structure of target compounds can enhance their therapeutic properties and efficacy.
Used in Organic Compounds Production:
In the field of organic chemistry, 5-methoxynaphthalen-1-amine serves as a building block for the production of a variety of organic compounds. Its unique structure facilitates the creation of complex molecules with specific functions and applications.
Used in Research and Development:
5-methoxynaphthalen-1-amine is also used in research settings to explore its potential biological activities. Scientists are investigating its pharmaceutical applications, which may lead to the development of new drugs and therapies.
Used in Chemical Reactions:
Due to its reactivity and structural features, 5-methoxynaphthalen-1-amine is employed in various chemical reactions to produce a range of products. Its versatility makes it a valuable component in the synthesis of different chemical entities.

Upstream product

• 4900-64-5 5-nitro-1-methoxynaphthalene 
• 22302-65-4 N-(5-hydroxynaphthalen-1-yl)acetamide 
• 83-55-6 5-amino-1-naphthol 
• 74-88-4 methyl iodide 
• 848086-82-8 tert-butyl (5-hydroxynaphthalen-1-yl)carbamate 
• 51687-73-1 N-(5-methoxynaphthalen-1-yl)acetamide 

Downstream Products

• 51687-73-1 N-(5-methoxynaphthalen-1-yl)acetamide 
• 103845-91-6 (5-Methoxy-naphthalen-1-yl)-[1-(3-nitro-phenyl)-meth-(Z)-ylidene]-amine 
• 89844-58-6 [1-(4-Ethoxy-phenyl)-meth-(Z)-ylidene]-(5-methoxy-naphthalen-1-yl)-amine 
• 103845-90-5 1-benzylideneamino-5-methoxynaphthalene 
• 1446746-10-6 8-chloro-N,N-dimethyl-4-((2-methyl-3-(trifluoromethyl)phenyl)amino)-1-naphthamide 
• 61735-52-2 1-chloro-5-methoxynaphthalene 
• 1338495-59-2 C₁₈H₁₇NO₃S 
• 1338495-67-2 C₂₅H₂₇NO₅S 
• 89844-61-1 2-(4-ethoxystyryl)-4-methoxybenzoindolium perchlorate 
• 87878-52-2 2-(4-methoxystyryl)-5-methoxybenzoindolium perchlorate 
• 89844-59-7 [1-(4-Ethoxy-phenyl)-meth-(Z)-ylidene]-(5-methoxy-naphthalen-1-yl)-amine; compound with perchloric acid 
• 89844-57-5 (5-Methoxy-naphthalen-1-yl)-[1-(4-methoxy-phenyl)-meth-(Z)-ylidene]-amine; compound with perchloric acid 

Relevant academic research and scientific papers

RhIII-Catalyzed Double Dehydrogenative Coupling of Free 1-Naphthylamines with α,β-Unsaturated Esters

The RhIII-catalyzed, consecutive double C?H oxidative coupling of free 1-naphthylamine and α,β-unsaturated esters through C?H/C?H and C?H/N?H bonds is reported. The one step reaction leads to the formation of biologically important alkylidene-1,2-dihydrobenzo[cd]indoles scaffolds. This efficient process is much more synthetically convenient and useful than others because the starting materials, such as 1-naphthylamine derivatives are readily available and the free amine serves as a directing group.

Monna, a potent and selective blocker for transmembrane protein with unknown function 16/anoctamin-1

Transmembrane protein with unknown function 16/anoctamin-1 (ANO1) is a protein widely expressed in mammalian tissues, and it has the properties of the classic calcium-activated chloride channel (CaCC). This protein has been implicated in numerous major physiological functions. However, the lack of effective and selective blockers has hindered a detailed study of the physiological functions of this channel. In this study, we have developed a potent and selective blocker for endogenous ANO1 in Xenopus laevis oocytes (xANO1) using a drug screening method we previously established (Oh et al., 2008). We have synthesized a number of anthranilic acid derivatives and have determined the correlation between biological activity and the nature and position of substituents in these derived compounds. A structure-activity relationship revealed novel chemical classes of xANO1 blockers. The derivatives contain a-NO2 group on position 5 of a naphthyl group-substituted anthranilic acid, and they fully blocked xANO1 chloride currents with an IC 5050 of 0.08 μM for xANO1. Selectivity tests revealed that other chloride channels such as bestrophin-1, chloride channel protein 2, and cystic fibrosis transmembrane conductance regulator were not appreciably blocked by 10～30 μM MONNA. The potent and selective blockers for ANO1 identified here should permit pharmacological dissection of ANO1/CaCC function and serve as potential candidates for drug therapy of related diseases such as hypertension, cystic fibrosis, bronchitis, asthma, and hyperalgesia.

CANNABINOID RECEPTOR MODULATORS

Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors of Formula (I).

CANNABINOID RECEPTOR MODULATORS

Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors of Formula (I).

Analogues of σ receptor ligand 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4- tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) with added polar functionality and reduced lipophilicity for potential use as positron emission tomography radiotracers

1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl] piperazine 1 (PB28) represents an excellent lead candidate for therapeutic and/or diagnostic applications in oncology. However, because its utility is limited by its relatively high de

GLYT1 TRANSPORTER INHIBITORS

The invention provides a compound of formula (I): or a salt, solvate or a physiologically functional derivative thereof, wherein R1 to R10 are as defined in the specification and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.

NAPHTHALENE AMINOALKYLENE ETHERS AND THIOETHERS, AND THEIR PHARMACEUTICAL USES

A class of naphthalene aminoalkylene ether and thioether compounds exhibiting pharmacological activity including anti-secretory and anti-ulcerogenic activity, pharmaceutical compositions comprising these compounds, and methods for the treatment of gastrointestinal hyperacidity and ulcerogenic disorders in mammals using said compositions are disclosed.